Monitoring in HIV patient populations at risk for metabolic syndrome secondary to concomitant protease inhibitor and second-generation antipsychotic therapy

Authors

  • Nasar Ansari
  • Divya Akula
  • Morgan Heitt
  • Christina Connel
  • John Bury
  • Kelly Murray

Abstract

Second-generation antipsychotics (SGAs) and protease inhibitors (PIs) cause metabolic side effects. These are compounded with concomitant therapy due to additive side effects and pharmacological interactions, potentially increasing serum SGA concentrations. People living with HIV (PLWH) are at higher risk for metabolic complications secondary to inflammation caused by the virus. The objective of this study is to explore the prevalence of metabolic syndrome with concurrent SGA and PI therapy and evaluate current risk management practices.

Downloads

Published

2023-12-11

Issue

Section

Pharmacotherapy